Acrivon Therapeutics, Inc. Common Stock

$1.76+10.00%(+$0.16)
TickerSpark Score
55/100
Mixed
90
Valuation
20
Profitability
30
Growth
84
Health
50
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACRV research report →

52-Week Range28% of range
Low $1.05
Current $1.76
High $3.56

Companywww.acrivon.com

Acrivon Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

CEO
Peter Blume-Jensen
IPO
2022
Employees
75
HQ
Watertown, MA, US

Price Chart

+40.80% · this period
$3.01$2.03$1.05May 20Nov 18May 20

Valuation

Market Cap
$55.54M
P/E
-0.88
P/S
0.00
P/B
0.71
EV/EBITDA
-0.28
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-64.43%
ROIC
-84.09%

Growth & Income

Revenue
$0 · 0.00%
Net Income
$-77,905,000 · 3.29%
EPS
$-2.02 · 3.81%
Op Income
$-84,114,000
FCF YoY
4.53%

Performance & Tape

52W High
$3.56
52W Low
$1.05
50D MA
$1.72
200D MA
$1.83
Beta
2.02
Avg Volume
791.44K

Get TickerSpark's AI analysis on ACRV

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
May 18, 26RA CAPITAL MANAGEMENT, L.P.other9,366
May 18, 26TOMSICEK MICHAEL JOHNother9,366
May 18, 26Shacham Sharonother9,366
May 18, 26Palani Santhoshother9,366
May 18, 26Magovcevic-Liebisch Ivanaother9,366
May 18, 26DiRocco Derekother9,366
May 18, 26BAUM CHARLES Mother9,366
May 18, 26Peterson Katharineother14,227
May 18, 26Mirza Mansoor Razaother38,817
May 18, 26Miller Maryother49,830

Our ACRV Coverage

We haven't published any research on ACRV yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate ACRV Report →

Similar Companies